Information Provided By:
Fly News Breaks for February 23, 2016
IMMY, RTRX
Feb 23, 2016 | 08:53 EDT
After conducting checks, JMP Securities says that Retrophin is well-positioned to defend its Thiola franchise against the much cheaper, compounded version that Imprimis Pharmaceuticals (IMMY) plans to launch in April. The firm says its feedback form one expert suggests that doctors will resist using a compounded version of the product due to the risks associated with compound pharmacies, lack of issues with accessing Thiola and the ability to measure the main ingredients in Thiola. JMP keeps a $28 price target and Outperform rating on the shares.
News For RTRX;IMMY From the Last 2 Days
There are no results for your query RTRX;IMMY